Clinical Trials
22 trialsNCT03960840 2026-06-04
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Phase 1/2 Active not recruiting
NCT04542824 2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT04661007 2026-05-18
J-MIND
Incyte Corporation
Phase 1/2 Active not recruiting
NCT06561425 2026-03-16
Atalanta-1
Lakefront Biotherapeutics NV
Phase 1/2 Active not recruiting
NCT05546268 2026-03-03
Study of Oral MRT-2359 in Selected Cancer Patients
Monte Rosa Therapeutics, Inc
Phase 1/2 Active not recruiting
NCT05658562 2026-02-13
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
Tanabe Pharma Corporation
Phase 1/2 Active not recruiting
NCT03842696 2026-01-27
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting
NCT05222555 2026-01-16
MINDway
Incyte Corporation
Phase 1/2 Active not recruiting
NCT04572763 2026-01-07
Copanlisib Plus Venetoclax in R/R DLBCL
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT03277729 2026-01-05
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Fred Hutchinson Cancer Center
Phase 1/2 Active not recruiting
NCT04787263 2025-12-02
CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML
Bambino Gesù Hospital and Research Institute
Phase 1/2 Active not recruiting
NCT05565417 2025-10-16
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
Phase 1/2 Active not recruiting
NCT04257578 2025-10-08
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
University of Washington
Phase 1/2 Active not recruiting
NCT03015896 2025-09-29
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT03147885 2025-09-29
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Active not recruiting
NCT05192486 2025-09-26
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2 Active not recruiting
NCT04446962 2025-09-25
LOC-R01
Institut Curie
Phase 1/2 Active not recruiting
NCT03162536 2025-09-08
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2 Active not recruiting
NCT04914741 2024-08-12
COALITION
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting
NCT05749549 2024-08-07
Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers
Shanghai Blueray Biopharma Co., Ltd.
Phase 1/2 Active not recruiting
NCT02628405 2024-07-01
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
Academic and Community Cancer Research United
Phase 1/2 Active not recruiting